COST-EFFECTIVENESS OF UNIVERSAL OR PHENOTYPE-DRIVEN SELECTION OF DUAL ANTIPLATELET TREATMENT IN ACUTE CORONARY SYNDROME

被引：0
|
作者：
Coleman, Craig I. [1 ]
Limone, Brendan [1 ]
Lee, Soyon [1 ]
机构：
[1] Univ Connecticut, Storrs, CT USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2013年 / 61卷 / 10期
关键词：
D O I：
10.1016/S0735-1097(13)60007-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：E6 / E6
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF UNIVERSAL OR GENOTYPE DRIVEN USE OF AVAILABLE DUAL ANTIPLATELET STRATEGIES IN PATIENTS WITH ACUTE CORONARY SYNDROME
    Lee, Soyon
    Dhamija, Asha
    Parsons, Katelyn
    King, Matthew
    Kaur, Rajbir
    Roberts, Matthew
    Coleman, Craig
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (13) : E483 - E483
  • [2] COST-EFFECTIVENESS OF UNIVERSAL VERSUS ASSAY-DRIVEN ANTIPLATELET THERAPY IN ACUTE CORONARY SYNDROME PATIENTS
    Coleman, C., I
    Limone, B. L.
    VALUE IN HEALTH, 2013, 16 (03) : A284 - A284
  • [3] Cost-Effectiveness of Universal and Platelet Reactivity Assay-Driven Antiplatelet Therapy in Acute Coronary Syndrome
    Coleman, Craig I.
    Limone, Brendan L.
    AMERICAN JOURNAL OF CARDIOLOGY, 2013, 112 (03): : 355 - 362
  • [4] Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome
    Kazi, Dhruv S.
    Garber, Alan M.
    Shah, Rashmee U.
    Dudley, R. Adams
    Mell, Matthew W.
    Rhee, Ceron
    Moshkevich, Solomon
    Boothroyd, Derek B.
    Owens, Douglas K.
    Hlatky, Mark A.
    ANNALS OF INTERNAL MEDICINE, 2014, 160 (04) : 221 - 232
  • [5] COST-EFFECTIVENESS OF GENOTYPE-DRIVEN ANTIPLATELET THERAPY FOR SECONDARY PREVENTION AFTER ACUTE CORONARY SYNDROME
    Crespin, D. J.
    Federspiel, J. J.
    Biddle, A. K.
    Jonas, D.
    Stearns, S. C.
    Rossi, J. S.
    VALUE IN HEALTH, 2010, 13 (03) : A162 - A162
  • [6] Cost-effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome
    Jiang, Minghuan
    You, Joyce H. S.
    PHARMACOGENOMICS, 2016, 17 (07) : 701 - 713
  • [7] COST-EFFECTIVENESS EVALUATION OF GENOTYPE-GUIDED ANTIPLATELET THERAPY VERSUS UNIVERSAL NEW ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME
    Jiang, M.
    You, J.
    VALUE IN HEALTH, 2015, 18 (03) : A20 - A20
  • [8] PANACEA OR PERSONALIZED MEDICINE? OPTIMIZING ANTIPLATELET THERAPY IN ACUTE CORONARY SYNDROME - A COST-EFFECTIVENESS ANALYSIS
    Kazi, Dhruv
    Garber, Alan M.
    Shah, Rashmee
    Rhee, Ceron
    Moshkevich, Solomon
    Mell, Matthew W.
    Boothroyd, Derek
    Owens, Douglas K.
    Hlatky, Mark
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (13) : E348 - E348
  • [9] Ticagrelor versus Genotype-Driven Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndrome: A Cost-Effectiveness Analysis
    Crespin, Daniel J.
    Federspiel, Jerome J.
    Biddle, Andrea K.
    Jonas, Daniel E.
    Rossi, Joseph S.
    VALUE IN HEALTH, 2011, 14 (04) : 483 - 491
  • [10] eNOS gene influences platelet phenotype in acute coronary syndrome patients on dual antiplatelet treatment
    Fatini, Cinzia
    Sticchi, Elena
    Bolli, Paola
    Marcucci, Rossella
    Giusti, Betti
    Paniccia, Rita
    Gori, Anna Maria
    Gensini, Gian Franco
    Abbate, Rosanna
    PLATELETS, 2009, 20 (08) : 548 - 554
12345